Recent News

• 05.28.2026 - Assembly Biosciences Announces Upcoming Investor Conference Presentations
• 05.26.2026 - Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
• 05.22.2026 - Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
• 05.22.2026 - Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
• 05.13.2026 - Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
• 05.11.2026 - Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
• 05.07.2026 - Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Recent Filings

• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.26.2026 - EX-99.1 EX-99.1
• 05.26.2026 - 8-K Current report
• 05.26.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.22.2026 - EX-99.1 EX-99.1
• 05.22.2026 - 8-K Current report
• 05.22.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.11.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]